WEST PHARMACEUTICAL SERVICES (WST)
US9553061055 - Common Stock
| MRQ (2024-3-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash Equivalents | 601.80M | 853.90M | 894.30M | 762.60M | 615.50M | |||
| Receivables | 524.00M | 512.00M | 507.40M | 489.00M | 385.30M | |||
| Inventories | 429.90M | 434.70M | 414.80M | 378.40M | 321.30M | |||
| Other Current Assets | 137.20M | 135.80M | 103.00M | 112.00M | 51.60M | |||
| Total Current Assets | 1.69B | 1.94B | 1.92B | 1.74B | 1.37B | |||
| Non-Current Assets | ||||||||
| PPE Net | 1.55B | 1.51B | 1.26B | 1.13B | 1.01B | |||
| Investments And Advances | 202.50M | 210.00M | 204.90M | 207.70M | 214.70M | |||
| Goodwill | 107.60M | 108.50M | 107.30M | 109.90M | 111.10M | |||
| Intangibles | 13.90M | 15.10M | 18.40M | 23.00M | 30.50M | |||
| Other Non-Current Assets | 40.00M | 47.00M | 104.00M | 104.40M | 52.30M | |||
| Total Non-Current Assets | 1.91B | 1.89B | 1.70B | 1.57B | 1.42B | |||
| TOTAL ASSETS | 3.60B | 3.83B | 3.62B | 3.31B | 2.79B | |||
| LIABILITIES | ||||||||
| Current Liabilities | ||||||||
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Current Portion Of LT Debt. | 133.40M | 134.00M | 2.20M | 44.20M | 2.30M | |||
| Accrued Expenses | 84.50M | 179.00M | 159.20M | 195.40M | 159.20M | |||
| Accounts Payable | 240.10M | 242.40M | 215.40M | 232.20M | 213.10M | |||
| Other Current Liabilities | 190.40M | 116.40M | 142.20M | 122.30M | 128.80M | |||
| Total Current Liabilities | 648.40M | 671.80M | 519.00M | 594.10M | 503.40M | |||
| Non-Current Liabilities | ||||||||
| Long Term Debt | 72.80M | 72.80M | 206.70M | 208.80M | 252.90M | |||
| Deferred Taxes/Income | 12.70M | 12.70M | 14.30M | 4.90M | 10.40M | |||
| Other Non-Current Liabilities | 187.80M | 191.20M | 191.90M | 170.60M | 172.60M | |||
| Total Non-Current Liabilities | 273.30M | 276.70M | 412.90M | 384.30M | 435.90M | |||
| TOTAL LIABILITIES | 921.70M | 948.50M | 931.90M | 978.40M | 939.30M | |||
| SHAREHOLDERS' EQUITY | ||||||||
| Retained Earnings | 3.62B | 3.52B | 2.99B | 2.46B | 1.85B | |||
| Additional Paid In Capital | 55.20M | 120.20M | 232.20M | 249.00M | 267.30M | |||
| Common Shares | 18.80M | 18.80M | 18.80M | 18.80M | 18.80M | |||
| Treasury Stock | -825.20M | -637.60M | -370.90M | -229.50M | -167.70M | |||
| Other Shareholders' Equity | -194.50M | -146.10M | -184.60M | -161.10M | -111.20M | |||
| Shares Outstanding | 73.00M | 73.50M | 74.10M | 74.20M | 74.00M | |||
| Tangible Book Value per Share | 35.06 | 37.52 | 34.54 | 29.68 | 23.15 | |||
| Total Shareholders' Equity | 2.68B | 2.88B | 2.68B | 2.34B | 1.85B | |||
| TOTAL LIABILITIES AND EQUITY | 3.60B | 3.83B | 3.62B | 3.31B | 2.79B | |||
| Statistics | ||||||||
| Debt/Equity | 0.03 | 0.03 | 0.08 | 0.09 | 0.14 | |||
| Current Ratio | 2.61 | 2.88 | 3.70 | 2.93 | 2.73 | |||
| Return On Assets (ROA) | 15.79% | 15.50% | 16.20% | 19.97% | 12.39% | |||
| Return On Equity (ROE) | 21.22% | 20.60% | 21.82% | 28.34% | 18.67% | |||
| Return On Invested Capital (ROIC) | 18.45% | 18.40% | 20.08% | 22.94% | 15.02% | |||
| Return On Invested Capital Ex Cash (ROICexc) | 23.17% | 25.21% | 28.22% | 31.87% | 20.55% | |||
| Return On Invested Capital Ex Cash + Goodwill (ROICexcg) | 24.44% | 26.64% | 29.93% | 34.20% | 22.44% | |||
All data in USD